Chlortetracycline Hydrochloride

CHEMBL2146063 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
515.3 g/mol
LogP
Phase
4

The hydrochloride salt form of chlortetracycline retains the broad-spectrum bacteriostatic activity of this early tetracycline antibiotic. In human medicine, it is now mainly found in topical ophthalmic preparations for conjunctivitis. Its systemic use has been replaced by newer tetracyclines with improved pharmacokinetics and tolerability.

Molekularmasse

515,3000 g/mol

TPSA

182,00 Ų

Wirkmechanismus

Binds reversibly to the 30S ribosomal subunit, blocking the attachment of aminoacyl-tRNA to the ribosomal acceptor (A) site. This inhibits bacterial protein synthesis in a bacteriostatic manner.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Binds reversibly to the 30S ribosomal subunit, blocking the attachment of aminoacyl-tRNA to the ribosomal acceptor (A) site. This inhibits bacterial protein synthesis in a bacteriostatic manner.

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)ccc(Cl)c4[C@@](C)(O)[C@H]3C[C@@H]12.Cl

InChI

InChI=1S/C22H23ClN2O8.ClH/c1-21(32)7-6-8-15(25(2)3)17(28)13(20(24)31)19(30)22(8,33)18(29)11(7)16(27)12-10(26)5-4-9(23)14(12)21;/h4-5,7-8,15,26,28-29,32-33H,6H2,1-3H3,(H2,24,31);1H/t7-,8-,15-,21-,22-;/m0./s1

Molecular Formula

C22H24Cl2N2O8

HBD / HBA

7 / 9

Rotierbare Bindungen

2

Schwere Atome

34

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

The hydrochloride salt form of chlortetracycline retains the broad-spectrum bacteriostatic activity of this early tetracycline antibiotic. In human medicine, it is now mainly found in topical ophthalmic preparations for conjunctivitis. Its systemic use has been replaced by newer tetracyclines with improved pharmacokinetics and tolerability.

Binds reversibly to the 30S ribosomal subunit, blocking the attachment of aminoacyl-tRNA to the ribosomal acceptor (A) site. This inhibits bacterial protein synthesis in a bacteriostatic manner.

Yes, Chlortetracycline Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2146063. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 54682468. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.